Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Literature DB >> 15767610

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Joel Lexchin¹.

Abstract

Mesh：

Year: 2005 PMID： 15767610 PMCID： PMC552890 DOI： 10.1503/cmaj.045021

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

9 in total

1. Timing of new black box warnings and withdrawals for prescription medications.

Authors: Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal: JAMA Date: 2002-05-01 Impact factor: 56.272

2. The safety of newly approved medicines: do recent market removals mean there is a problem?

Authors: M A Friedman; J Woodcock; M M Lumpkin; J E Shuren; A E Hass; L J Thompson
Journal: JAMA Date: 1999-05-12 Impact factor: 56.272

3. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?

Authors: Joel Lexchin
Journal: Can Fam Physician Date: 2002-09 Impact factor: 3.275

4. Canadian and US drug approval times and safety considerations.

Authors: Nigel S B Rawson; Kenneth I Kaitin
Journal: Ann Pharmacother Date: 2003-10 Impact factor: 3.154

5. New directions in drug approval.

Authors: Joel Lexchin
Journal: CMAJ Date: 2004-08-03 Impact factor: 8.262

6. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.

Authors: John Abraham; Courtney Davis
Journal: Soc Sci Med Date: 2005-03-02 Impact factor: 4.634

7. The administration and development of federal statutes on foods and drugs in Canada.

Authors: L I Pugsley
Journal: Med Serv J Can Date: 1967-03

8. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Authors: O M Bakke; M Manocchia; F de Abajo; K I Kaitin; L Lasagna
Journal: Clin Pharmacol Ther Date: 1995-07 Impact factor: 6.875

9. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety.

Authors: O M Bakke; W M Wardell; L Lasagna
Journal: Clin Pharmacol Ther Date: 1984-05 Impact factor: 6.875

9 in total

23 in total

1. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors: Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal: Drug Saf Date: 2010-06-01 Impact factor: 5.606

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

1. Timing of new black box warnings and withdrawals for prescription medications.

2. The safety of newly approved medicines: do recent market removals mean there is a problem?

3. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?

4. Canadian and US drug approval times and safety considerations.

5. New directions in drug approval.

6. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.

7. The administration and development of federal statutes on foods and drugs in Canada.

8. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

9. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety.

1. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Review 2. Case series in drug safety: a review to determine characteristics and quality.

3. Smart regulation: will the government's strategy work?

4. Is there still a role for spontaneous reporting of adverse drug reactions?

5. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

6. Novel in vitro cardiovascular constructs composed of vascular-like networks and cardiomyocytes.

7. Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada.

8. Ascertainment of acute liver injury in two European primary care databases.

9. A Review of Pharmacovigilance.

Review 10. Adverse drug reactions: The importance of maintaining pharmacovigilance.